Form 4: Alector Director Mark Altmeyer Receives Significant Equity Grant

Alector, Inc. Director Mark Altmeyer was granted 28,700 restricted stock units and options to purchase 9,450 shares of common stock, aligning his interests with shareholders.

Summary

• Mark Altmeyer, a Director of Alector, Inc. (ALEC), acquired 28,700 shares of common stock in the form of Restricted Stock Units (RSUs) and options to purchase 9,450 shares of common stock on June 11, 2025.
• The RSUs were granted at a price of $0.00 and are set to vest on the earlier of June 11, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The stock options have an exercise price of $1.63 per share and will vest in 12 equal monthly installments beginning on July 11, 2025, or fully vest on the earlier of the one-year anniversary of the grant date or the next annual meeting.
• Following these transactions, Mr. Altmeyer's direct beneficial ownership stands at 69,950 shares of common stock and 9,450 stock options.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive sign of aligning management interests with shareholders. It does not contain any negative financial news or operational setbacks.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with the long-term performance of Alector, Inc.
• Equity compensation is a common practice to incentivize directors and retain key talent, fostering commitment to the company's success.

Risks

• The ultimate value of the equity compensation is contingent upon the future performance of Alector, Inc.'s stock price.
• The vesting conditions mean that the full benefit of the grant is not immediate and depends on continued service or the achievement of specific dates.

Future Outlook

The vesting schedules for the RSUs and stock options indicate future dates when these equity awards will become fully owned by the director, aligning their long-term commitment with the company's performance and future value creation.

Industry Context

Equity grants, including Restricted Stock Units (RSUs) and stock options, are a standard component of executive and director compensation packages across various industries, particularly in biotechnology and growth-oriented companies like Alector, Inc. This practice is designed to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success and shareholder value of the company.

Comparison to Industry Standards

• This type of equity grant (RSUs and stock options with vesting schedules) is a common compensation mechanism for directors in the biotechnology and pharmaceutical sectors.
• While specific grant sizes vary based on company size, stage of development, and individual roles, the structure of these awards is consistent with broader industry practices aimed at aligning director incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific transaction.

Next Steps

• Vesting of 28,700 Restricted Stock Units (RSUs) on the earlier of June 11, 2026, or the date of Alector's next annual meeting of stockholders.
• Vesting of 9,450 stock options in 12 equal monthly installments beginning July 11, 2025, or fully vesting on the earlier of the one-year anniversary of the grant date or the next annual meeting.

Key Dates

Keywords

Alector Inc., ALEC, Form 4, Insider Trading, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Beneficial Ownership, Mark Altmeyer